Cervical cancer
Conditions
Interventions
Experimental group:Radical hysterectomy
Sponsors
Cancer hospital chinese academy of medical sciences,shenzhen center
Eligibility
Sex/Gender
Female
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. The subjects voluntarily participated in this study, signed the informed consent form, had good compliance, and cooperated with the follow-up. 2. Female patients aged 18-65 years old. 3. Clinically diagnosed with FIGO (2018) stage IIICr cervical cancer (evaluated for lymph node metastasis through imaging examination). 4. ECOG status 0-1 / Karnofsky score >= 80. 5. Preoperative pathological diagnosis of cervical squamous cell carcinoma, cervical adenosquamous cell carcinoma or cervical adenocarcinoma. 6. Patients with cervical cancer who received initial treatment or those who underwent neoadjuvant chemotherapy (if PD-L1 positive / CPS score >= 1, immunotherapy combined with neoadjuvant chemotherapy was possible). 7. Preoperative imaging and physical examination showed no involvement of the parametrium and no involvement of the lower 1/3 of the vagina.
Exclusion criteria
Exclusion criteria: 1. Patients who have previously received pelvic/abdominal radiotherapy or chemotherapy; 2. CT, MRI or PET scans indicate distant metastasis; 3. Had a second malignant tumor in the past 5 years (excluding thyroid cancer or carcinoma in situ during the same period) or had any signs of recurrence or activity; 4. Have severe systemic diseases; 5. Clinically diagnosed with primary cervical cancer, FIGO (2018) stage IIB, IIIA, IIIB (with parametrial involvement, lower 1/3 of the vagina involvement and pelvic wall involvement); 6. Pregnant; 7. Any factor affecting informed consent, compliance with the research protocol or inability to follow up on schedule; 8. Have any active infectious diseases or incurable severe inflammation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival;Quality of life;Complications from surgery/radiation ± chemotherapy;The accuracy of radiological diagnosis of lymph nodes;Pelvic/retroperitoneal lymph node recurrence rate; | — |
Countries
China
Contacts
Public ContactLi Sun
Cancer hospital chinese academy of medical sciences,shenzhen center
Outcome results
None listed